Sequenta, Inc. and its academic collaborators will share data about the use of the company’s next-generation sequencing-based assay for minimal residual disease (MRD) in lymphoid cancers (available clinically in the United States as the ClonoSIGHT™ test) in one oral and three poster presentations at the 19th Congress of the European Hematology Association (EHA) being held June 12-15 in Milan, Italy.
Help employers find you! Check out all the jobs and post your resume.
